- Home
- VTRS vs CFR Comparison
VTRS vs CFR Comparison
Compare VTRS & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- CFR
- Stock Information
- Founded
- VTRS 1961
- CFR 1868
- Country
- VTRS United States
- CFR United States
- Employees
- VTRS N/A
- CFR N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- CFR Major Banks
- Sector
- VTRS Health Care
- CFR Finance
- Exchange
- VTRS Nasdaq
- CFR Nasdaq
- Market Cap
- VTRS 9.0B
- CFR 7.9B
- IPO Year
- VTRS N/A
- CFR N/A
- Fundamental
- Price
- VTRS $8.79
- CFR $126.93
- Analyst Decision
- VTRS Hold
- CFR Hold
- Analyst Count
- VTRS 4
- CFR 15
- Target Price
- VTRS $10.50
- CFR $131.93
- AVG Volume (30 Days)
- VTRS 17.6M
- CFR 346.6K
- Earning Date
- VTRS 05-08-2025
- CFR 07-24-2025
- Dividend Yield
- VTRS 5.46%
- CFR 3.15%
- EPS Growth
- VTRS N/A
- CFR 7.71
- EPS
- VTRS N/A
- CFR 9.11
- Revenue
- VTRS $14,330,200,000.00
- CFR $2,038,108,000.00
- Revenue This Year
- VTRS N/A
- CFR $13.57
- Revenue Next Year
- VTRS $1.85
- CFR $4.58
- P/E Ratio
- VTRS N/A
- CFR $13.94
- Revenue Growth
- VTRS N/A
- CFR 5.45
- 52 Week Low
- VTRS $6.85
- CFR $94.09
- 52 Week High
- VTRS $13.55
- CFR $147.64
- Technical
- Relative Strength Index (RSI)
- VTRS 54.57
- CFR 53.04
- Support Level
- VTRS $8.19
- CFR $123.99
- Resistance Level
- VTRS $8.85
- CFR $130.35
- Average True Range (ATR)
- VTRS 0.25
- CFR 2.28
- MACD
- VTRS 0.00
- CFR -0.40
- Stochastic Oscillator
- VTRS 65.22
- CFR 37.48
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.